Northland Securities reaffirmed their hold rating on shares of Zynex (OTCMKTS:ZYXI) in a research report released on Wednesday morning, reports. Northland Securities currently has a $22.50 target price on the stock.

Several other equities research analysts have also commented on the company. Zacks Investment Research upgraded Zynex from a hold rating to a buy rating and set a $12.00 price objective for the company in a research note on Tuesday, March 31st. Piper Sandler assumed coverage on Zynex in a report on Monday, July 20th. They issued an overweight rating and a $30.00 price objective on the stock. B. Riley cut Zynex from a buy rating to a neutral rating in a research note on Monday, July 13th. They noted that the move was a valuation call. Finally, HC Wainwright decreased their price target on Zynex from $30.00 to $25.00 and set a neutral rating on the stock in a research note on Wednesday. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Zynex presently has an average rating of Buy and a consensus price target of $23.50.

Shares of ZYXI opened at $19.12 on Wednesday. The stock has a 50-day moving average of $23.36 and a two-hundred day moving average of $16.05. Zynex has a one year low of $7.51 and a one year high of $29.73. The stock has a market cap of $663.58 million, a P/E ratio of 86.91 and a beta of 1.05.

Zynex (OTCMKTS:ZYXI) last issued its quarterly earnings data on Tuesday, July 28th. The company reported $0.09 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.09. Zynex had a return on equity of 152.81% and a net margin of 33.33%. The business had revenue of $19.26 million during the quarter, compared to analysts’ expectations of $19.12 million. As a group, equities research analysts predict that Zynex will post 0.28 EPS for the current fiscal year.

In other Zynex news, CEO Thomas Sandgaard sold 1,250,000 shares of Zynex stock in a transaction that occurred on Tuesday, July 14th. The shares were sold at an average price of $22.00, for a total value of $27,500,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Daniel J. Moorhead bought 2,733 shares of the stock in a transaction on Thursday, July 30th. The stock was purchased at an average cost of $18.11 per share, with a total value of $49,494.63. Following the completion of the purchase, the chief financial officer now directly owns 19,001 shares in the company, valued at approximately $344,108.11. The disclosure for this purchase can be found here.

Large investors have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA lifted its holdings in Zynex by 121.9% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,866 shares of the company’s stock worth $54,000 after buying an additional 2,673 shares in the last quarter. Invesco Ltd. lifted its stake in shares of Zynex by 258.8% in the 1st quarter. Invesco Ltd. now owns 67,937 shares of the company’s stock worth $752,000 after acquiring an additional 49,002 shares during the period. Advisor Group Holdings Inc. acquired a new stake in Zynex during the first quarter valued at approximately $617,000. AQR Capital Management LLC raised its holdings in shares of Zynex by 61.2% during the first quarter. AQR Capital Management LLC now owns 79,254 shares of the company’s stock valued at $877,000 after acquiring an additional 30,079 shares during the period. Finally, New York State Teachers Retirement System acquired a new stake in shares of Zynex during the second quarter valued at approximately $1,028,000. Institutional investors and hedge funds own 0.05% of the company’s stock.

Zynex Company Profile

Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.

Recommended Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with's FREE daily email newsletter.